Veru announces steven b. heymsfield m.d.

Miami, fl, may 15, 2024 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced steven b. heymsfield, m.d., a professor and the director of the body composition-metabolism laboratory at the pennington biomedical research center in baton rouge, louisiana, as the principal investigator for the company's phase 2b clinical trial of enobosarm to preserve muscle while augmenting fat loss in patients receiving a glp-1 ra for weight loss.
VERU Ratings Summary
VERU Quant Ranking